$KAPA
Kairos Pharma, Ltd.
XASE
Why is KAPA down today? It is at $0.235 (-19.00%), and our scanner flagged it 4 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KAPA spikes, and full due diligence on KAPA — key stats, earnings, dilution and insider activity. Free.
Get free $KAPA alerts the moment volume spikes
Our scanner flagged $KAPA 4 times in the last 30 days. Create a free account to track $KAPA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $0.235
- Change today
- -19.00%
- Previous close
- $0.290
- 52-week range
- $0.270 – $2.11
- Market cap
- $7M
- Institutional own.
- 4.70%
- Total held
- 8.7%
- Tradeable float
- 21.6M 91% of shares · after 4% insiders + 5% institutions
- Short interest
- 518K ▲ +169% vs prior · as of 2026-07-31
- Short % of float
- 2.4%
- Days to cover
- 1.0d
- Avg daily volume
- 942K
- Exchange
- XASE
- 5m
- 0.0x
- 15m
- 0.0x
- 1hthin
- 0.1x
- 1D
- 6.6x
Get free KAPA + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $KAPA down today?
Here is the latest on KAPA from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystPharma Announces 1-for-7 Reverse Stock SplitReported of fractional shares. Following the Reverse Stock Split, the par value of the common stock will remain unchanged at $0.001 par valueReverse split 1-for-3Status pending stockholder approval, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
0 buys, 0 sells last 3 months (9/0 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Yu John S Officer | Acquired (grant/award) | +191K 0.8% of company | added 100% | 230K | n/a | Oct 8, 25 |
Samuelson Doug Officer | Acquired (grant/award) | +153K 0.6% of company | added 100% | 293K | n/a | Oct 8, 25 |
Singhvi Rahul Director | Acquired (grant/award) | +19K 0.08% of company | added 63% | 49K | n/a | Oct 8, 25 |
Keyoung Hansoo Michael Director | Acquired (grant/award) | +19K 0.08% of company | added 100% | 29K | n/a | Oct 8, 25 |
Murali Ramachandran Officer | Acquired (grant/award) | +153K 0.6% of company | added 100% | 300K | n/a | Oct 8, 25 |
Bae Hyun W. Director | Acquired (grant/award) | +19K 0.08% of company | added 35% | 73K | n/a | Oct 8, 25 |
Bhowmick Neil Officer | Acquired (grant/award) | +172K 0.7% of company | added 15% | 1.31M | n/a | Oct 8, 25 |
Keyoung Hansoo Michael Director | Acquired (grant/award) | +10K 0.04% of company | n/a | 10K | n/a | Sep 16, 25 |
Bae Hyun W. Director | Acquired (grant/award) | +10K 0.04% of company | added 23% | 54K | n/a | Sep 16, 25 |
Yu John S Officer | Acquired (grant/award) | +14K 0.06% of company | added 0.3% | 5.36M | n/a | Jan 1, 25 |
Murali Ramachandran Officer | Acquired (grant/award) | +14K 0.06% of company | added 11% | 147K | n/a | Jan 1, 25 |
Bhowmick Neil Officer | Acquired (grant/award) | +14K 0.06% of company | added 1.2% | 1.14M | n/a | Jan 1, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfRecent share offering + active shelf on file — the company raised capital and can raise more. If $KAPA runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 1,835,714 new shares (adjusted for the later reverse split)
- At-the-market (ATM) program — sells new shares into the market gradually over time · About $4.5M in size · Baby-shelf capped: no more than one third of public float in any 12 months
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$KAPA Sentiment
BearishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$KAPA Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
KAPA stock FAQ
Why is $KAPA down today?
Here is the latest on KAPA from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
What is the KAPA stock price today?
KAPA last traded at $0.235, down 19.00% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live KAPA alerts?
The KAPA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KAPA 4 times in the last 30 days.
What exchange is KAPA on?
KAPA (Kairos Pharma, Ltd.) trades on XASE, with a market cap of about $7M.
Is KAPA good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KAPA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.